| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| ln Vitro |
TAS-103 is a DNA topoisomerase I/II dual inhibitor. TAS-103 exhibits activity on CCRF-CEM cells at concentrations 0.1-10 μM, with an IC50 of 5 nM. Individual CCRF-CEM cells exhibit significantly higher levels of topo IIα FITC immunofluorescence when exposed to TAS-103 (0.1 μM)[1]. Lewis lung carcinoma (LLC) cells are highly susceptible to TAS-103 (0.01-1 μM) cytotoxicity, and liposomal TAS-103 is nearly twice as active as free TAS-103[2]. TAS-103, with an IC50 of 40 nM, inhibits the viability of HeLa cells. TAS-103 (10 μM) causes destabilization of SRP14 and SRP19 and their eventual degradation, as well as disrupts the formation of signal recognition particle (SRP) complexes[3].
The half‑maximal effective concentration (EC₅₀) of 12 in H1792 cells is 0.32 ± 0.01 μM (Fig. 4i). |
|---|---|
| ln Vivo |
TAS-103 (30 mg/kg, i.v.) causes a noticeable reduction in body weight without causing a noticeable tumor growth suppression in mice harboring Lewis lung carcinoma (LLC) cells, and liposomal TAS-103 is more active than free TAS-103[2].
At doses near the ED₅₀ for anabolic activity (e.g., 0.5 mg/day and below), S‑4 did not cause significant suppression of luteinizing hormone (LH) or follicle‑stimulating hormone (FSH). At higher doses (≥0.75 mg/day), partial LH suppression was observed, but FSH remained largely unchanged. No drug‑related changes in body weight or non‑reproductive organ weights (liver, heart, kidney, spleen, lungs) were observed [1]. |
| Cell Assay |
The RPMI-1640 medium containing 3 mM l-glutamine, 10% foetal bovine serum, 50 U/mL penicillin, and 40 μg/mL streptomycin is used to cultivate CCRF-CEM human acute lymphoblastic leukemia cells. The cells are grown at 37°C in a humidified environment with 5% CO2. The DMSO dissolves TAS-103, CPT, and DACA. After two hours, either drug is applied to cells that are exponentially growing (approximately 5 × 105). Two centrifugations (400 × g, 3 min) in cold phosphate-buffered saline are used to wash cells twice after drug exposure[1].
|
| Animal Protocol |
Male C57BL/6 mice, aged five weeks, receive a subcutaneous injection of 0.2 mL of a suspension containing 5×106 cells/mL of diluted Lewislung carcinoma (LLC) cells, made using DMEM. The tumor-bearing mice are given intravenous injections of liposomal TAS-103 (0.2 mL/mouse, 30 mg/kg as TAS-103), free TAS-103, or PBS on days 4, 8, and 12 following tumor implantation. Every day after that, the tumor volume in each mouse is tracked, along with any changes in body weight that may indicate a side effect. One computes the tumor volume [2].
|
| References |
|
| Additional Infomation |
See also: Tas-103 (Notes moved to).
|
| Molecular Formula |
C20H192N3O2
|
|
|---|---|---|
| Molecular Weight |
333.38
|
|
| Exact Mass |
333.147
|
|
| CAS # |
174634-08-3
|
|
| Related CAS # |
|
|
| PubChem CID |
135413533
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
589.5±50.0 °C at 760 mmHg
|
|
| Flash Point |
310.3±30.1 °C
|
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
|
| Index of Refraction |
1.734
|
|
| LogP |
2.71
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
25
|
|
| Complexity |
497
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(C1=C2C3=CC=C(O)C=C3N=C1NCCN(C)C)C4=C2C=CC=C4
|
|
| InChi Key |
ROWSTIYZUWEOMM-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H19N3O2/c1-23(2)10-9-21-20-18-17(13-5-3-4-6-14(13)19(18)25)15-8-7-12(24)11-16(15)22-20/h3-8,11,24H,9-10H2,1-2H3,(H,21,22)
|
|
| Chemical Name |
6-[2-(dimethylamino)ethylamino]-3-hydroxyindeno[2,1-c]quinolin-7-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Structures of the chemical compounds and preparation of TAS-1-3383-fixed latex beads.Mol Pharmacol.2008 Mar;73(3):987-94. |
|---|
 Affinity purification using TAS-1-3383-fixed beads.Mol Pharmacol.2008 Mar;73(3):987-94. |
 Effects of TAS-103 on the interactions between SRP54 and other subunits.Mol Pharmacol.2008 Mar;73(3):987-94. |
 Effects of TAS-103 on the SRP complex.Mol Pharmacol.2008 Mar;73(3):987-94. |
|---|
 Effects of TAS-103 and knockdowns of SRP14 or SRP54 on the translocation of IL-6-FLAG.Mol Pharmacol.2008 Mar;73(3):987-94. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
